Kayentis finalized its round of funding in february
Kayentis finalized in February 2015 a round of funding with the arrival of Extens, a fund dedicated to e-health, alongside Seventure Partners, a shareholder since 2007, and business angels (new and already present in the shareholdings).
Guillaume Juge, director of Kayentis, said, “we are very happy to welcome Extens, whose focus on e-health completes our repositioning on the pharma market.”
Arnaud Houette, managing director and associate of Extens exclaimed, “Kayentis has been able to reinvent itself and we have faith in Guillaume Juge to pursue the company’s transformation, particularly concerning international business development.”
About Extens (www.extens.eu)
Extens is an investment fund exclusively devoted to the e-health sector. Extens invests amounts ranging from 1 to 7 million euros in profitable SME’s or those soon to become profitable with a level of turnover between 1 and 20 million euros. Its core target: software applications for hospitals, business process software for health professionals and solutions to accompany home care or mobility. Kayentis is the second investment in its portfolio after Enovacom in March 2014.
About Seventure Partners (www.seventure.fr)
An active partner of innovative companies with high growth potential, Seventure Partners has been investing in two main fields of business since 1997: the digital economy in France and Germany, and life sciences throughout Europe. Managing more than €515M as of 31 December 2014, Seventure Partners has become one of the main European players in innovation capital. Seventure Partners is a subsidiary of Natixis Global Asset Management. Natixis is the bank of investment, management and financial services in the BPCE group.
Guillaume JUGE, CEO – Kayentis
Last update : 17 November 2015